期刊文献+

吉非替尼中残留溶剂的GC法测定 被引量:2

Determination of Residual Organic Solvents in Gefitinib by GC
原文传递
导出
摘要 建立了气相色谱法测定吉非替尼生产中所使用的10种有机溶剂和1个起始原料N-(3-氯丙基)吗啉的残留量。使用DB-624毛细管色谱柱,采用毛细管直接进样,以N-甲基吡咯烷酮∶氯仿(1∶99)为溶剂,程序升温,测定DMF、DMSO和N-(3-氯丙基)吗啉。上述3种物质的回收率为99.6%~101.8%,RSD均小于2.8%。同样使用DB-624毛细管色谱柱,采用毛细管顶空进样,以1%N-甲基吡咯烷酮水溶液为溶剂,程序升温,测定甲醇、丙酮、异丙醇、二氯甲烷、甲基叔丁醚、正己烷、氯仿和正丁醇。上述8种有机溶剂完全分离,回收率为98.2%~109.6%,RSD均小于4.2%。 A GC method was established for the determination of ten residual organic solvents and a starting material N- (3-chloropropyl) morpholine in gefitinib. DMF, DMSO and N- (3-chloropropyl) morpholine were quantitatively determined by direct sampling gas chromatography (D-GC) on a DB-624 column, with 1-methyl-2- pyrrolidinone : chloroform (1 : 99) as the solvent and temperature programmed control. Their average recoveries were 99.6% - 101.8%, with RSDs less than 2.8%. Methanol, acetone, isopropanol, dichloromethane, tert-butyl methyl ether, n-hexane, chloroform and n-butanol were quantitatively determined by headspace gas chromatography (HS-GC) on a DB-624 column, with 1% 1-methyl-2-pyrrolidinone aqueous solution as the solvent and temperature programmed control. The above eight organic solvents were completely separated. Their average recoveries were 98.2 % - 109.6 %, with RSDs less than 4.2%.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2015年第11期1232-1235,共4页 Chinese Journal of Pharmaceuticals
基金 国家"重大新药创制"科技重大专项(2011ZX09401-306)
关键词 吉非替尼 残留溶剂 气相色谱 测定 gefitinib residual organic solvent gas chromatography determination
  • 相关文献

参考文献4

二级参考文献19

  • 1张晓彤,李龙芸,穆新林,王树兰.ZD1839(Iressa)在晚期非小细胞肺癌治疗中的应用[J].中国肺癌杂志,2004,7(4):309-312. 被引量:12
  • 2郑迪,山鸟忠宏,平岛智德,瓜生恭章,松井薰,新田隆,小林政司,笹田真滋,潼本宜之,古川贡,大场雄一郎,周彩存.Iressa单药治疗化疗失败后的晚期非小细胞肺癌[J].中国肺癌杂志,2004,7(4):313-317. 被引量:10
  • 3张保国,徐晋,姚乐申.恶性肿瘤患者血清中肝细胞生长因子定量测定的临床价值[J].实用医技杂志,2005,12(01A):17-18. 被引量:3
  • 4ZHANG Yu-hua,WEI Wei,XU Hao,WANG Yan-yan,WU Wen-xi.Inducing effects of hepatocyte growth factor on the expression of vascular endothelial growth factor in human colorectal carcinoma cells through MEK and PI3K signaling pathways[J].Chinese Medical Journal,2007(9):743-748. 被引量:13
  • 5Baselga J. New technologies in epidermal growth factor receptor targeted cancer therapy [ J ]. J Clin Oncol, 2000, 18 ( suppl 21 ) :54 -59.
  • 6Sako Y, Minoghchi S, Yanagida T. Single-molecule imaging of EGFR signaling on the surface of living cell [ J ]. Nat Cell Biol,2002, 2(3) :168 - 172.
  • 7Herdst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors : results of a phase Ⅰ trial [ J ]. J Clin Oncol, 2002, 10(18) : 599 -602.
  • 8Fukuoka M, Yano S, Giaccone G, et al. Mulit-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [ J ]. J Clin Oncol,2003, 21 (12): 2237- 2246.
  • 9Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib an inhibitor of the epidermal growth factor receptor tyrosine kinase in symptomatic patients with non-small cell lung cancer a randomized trial[J]. JAMA, 2003, 290(16):2149-2158.
  • 10Lorusso PM, Herbst RS, Rischin D, et al. Improvements in quality of life and disease-related symptoms in phase Ⅰ trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small-cell lung cancer and other solid tumors[J]. Clin cancer Res, 2003, 9(6) :2040 -2048.

共引文献43

同被引文献15

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部